NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Draig Therapeutics

Draig Therapeutics

Private
CardiffHealthcare & Life Scienceshttps://draigtherapeutics.com/

Last Round

Series B

Jul 14, 2026

Total Funding Raised

$205M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Draig Therapeutics is a biotechnology company that develops small molecule therapies for neuropsychiatric disorders, including major depressive disorder.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug deliverybiotechnologydrug formulationbiotechdrug developmenttherapeutic candidatesbioavailabilitydrug discoveryclinical trialspharmaceutical R&Ddrug licensingbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Draig Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Draig Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Draig Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 14, 2026
Series AJun 18, 2025
SeedSep 1, 2024

Key People

Founding team and executive leadership

Simon Ward

Founder Chief Scientific Development Officer (CSDO)

Founding Team

Dave Watson

Chief Operating Officer

Executive Team

Draig Therapeutics Investors

Notable investors and investment history

Draig Therapeutics investors
InvestorRounds
Janus Henderson GroupSeries B
SV Health InvestorsSeries A, Seed
Intermediate Capital GroupSeries A
British Business BankSeries B
Deep Track CapitalSeries B
Jefferson Life SciencesSeries B
Canaan PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    Monthly visitors increased 127% MoM, reaching 2.1K.

  • May 9, 2026

    Grew 22% QoQ, from 32 to 39 employees.

Draig Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Draig Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Draig Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCardiff
Employee Range41
Year Founded2024
Last FundingJul 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.